Hepatitis D peptide evidence
Bulevirtide for Hepatitis D: Hepcludex Evidence, Label Status, and Safety Limits
A source-backed guide to bulevirtide and Hepcludex for chronic hepatitis D: EU label status, NTCP entry inhibition, MYR301 trial evidence, post-treatment relapse, and claim limits.
Bulevirtide is one of the clearer examples of a peptide-related antiviral medicine with a real regulatory record and a narrow clinical context. It is sold in the European Union as Hepcludex for chronic hepatitis D virus infection in patients with compensated liver disease, after HDV RNA has been confirmed. That is a much more specific claim than "liver support" or "antiviral peptide" marketing.
Search interest around bulevirtide usually clusters around Hepcludex approval, hepatitis D treatment, HDV RNA response, NTCP entry inhibition, injection reactions, bile acids, interferon combination therapy, and whether treatment can stop after a defined course. Those are useful questions. They need hepatology sources, not a peptide-market shortcut.
The important distinction is category. Hepcludex is a prescription medicine with regulator-reviewed product information. A peptide sold as a research material is not the same thing. The same category filter applies across the approved, investigational, compounded, and research peptides guide, the COA red flags guide, and the study-reading guide.
Bulevirtide also belongs in a different evidence lane from immune-support peptide claims. Thymosin alpha-1, LL-37, and KPV are discussed online through immune modulation and inflammation claims. Bulevirtide has a defined antiviral entry-inhibition mechanism in an HDV population, so its evidence should be read on its own terms.
Evidence Snapshot
| Common claim | Evidence picture | Boundary |
|---|---|---|
| Bulevirtide is simply a hepatitis B drug. | EMA describes Hepcludex as an antiviral medicine for chronic hepatitis D virus infection in patients with compensated liver disease when HDV RNA is confirmed. | HDV depends on hepatitis B surface antigen, but the claim being evaluated is chronic hepatitis D treatment, not broad hepatitis B cure language. |
| Blocking viral entry means the infection is cured. | Bulevirtide blocks the liver-cell entry receptor used by HDV and HBV, and trials report virologic and biochemical response while treatment continues. | Post-treatment MYR301 follow-up found response rates fell after stopping therapy. Entry inhibition is not the same as durable eradication. |
| A short course is already established. | Phase 3 data through 96 and 144 weeks support longer-term on-treatment response assessment. | Optimal duration, stopping rules, and relapse prediction remain clinical questions, especially when HDV RNA becomes undetectable late in treatment. |
| Research-market bulevirtide can be evaluated like Hepcludex. | Hepcludex is a prescription product with product information, monitoring language, storage, route, and regulator-reviewed safety context. | A seller vial, COA, or sequence listing does not recreate the studied product, patient selection, liver monitoring, or hepatology setting. |
| Combination therapy removes the uncertainty. | A phase 2 study reported higher off-treatment HDV RNA undetectability in some bulevirtide plus pegylated interferon arms. | Interferon has its own eligibility, tolerability, and monitoring issues, so combination data should not be turned into generic peptide advice. |
What Bulevirtide Is
Bulevirtide, formerly known as myrcludex B, is a first-in-class entry inhibitor. The core idea is not general immune stimulation. The molecule attaches to and blocks the sodium taurocholate cotransporting polypeptide receptor, often shortened to NTCP, which hepatitis delta virus and hepatitis B virus use to enter liver cells. By blocking entry, bulevirtide limits the spread of HDV infection within the liver.
HDV biology explains why hepatitis B appears in the discussion. HDV is incomplete on its own and depends on hepatitis B virus surface antigen for its life cycle. That does not make every hepatitis B claim a bulevirtide claim. The EMA overview describes Hepcludex for chronic HDV infection when HDV RNA is confirmed, in patients with compensated liver disease.
Mechanistic plausibility matters, but it does not settle clinical outcomes. A receptor diagram cannot define who should be treated, how long treatment should continue, what happens after discontinuation, how to combine with HBV therapy, or how to monitor liver inflammation. Those questions come from human trials, product information, and specialist care.
Route and product identity matter too. Hepcludex is given as a daily subcutaneous injection under prescription supervision. The label and product information sit inside an HDV diagnosis, liver disease staging, HBV coinfection context, monitoring plan, adverse-event review, and regional authorization. None of that is created by peptide sequence identity alone.
Current Label And Authorization Status
The EMA page checked for this run lists Hepcludex as authorized for use in the European Union. The overview states that it is used for chronic HDV infection in adults and children from 3 years of age and weighing at least 10 kg who have compensated liver disease, with HDV RNA confirmed by blood tests. Treatment should be started by a doctor experienced in HDV management.
The authorization history is also relevant. Hepcludex received conditional EU marketing authorization in July 2020, then switched to standard marketing authorization in July 2023 after additional evidence was provided. The EMA product information was last updated in March 2026. That makes the official-source frame more current than many older peptide summaries.
Label geography should be stated plainly. The 2026 MYR301 publication abstract lists bulevirtide 2 mg daily as approved in Europe, Australia, Russia, and Canada for compensated chronic hepatitis D. This page did not identify a current U.S. FDA Hepcludex label during source review. That distinction matters because a drug can be authorized in one region, investigational or unavailable in another, and marketed online in a third context.
The EMA overview says treatment should continue for as long as the patient benefits from it. That phrase is important because it does not define a universal short course. It points back to liver specialist judgment, ongoing response, tolerability, and the evolving evidence on stopping therapy.
Human Evidence And What It Shows
The evidence base includes more than a mechanism paper. Early authorization was supported by studies showing reductions in HDV RNA and ALT, a liver enzyme used as a marker of liver inflammation. The EMA overview summarizes two main adult studies and a larger confirmatory study, including the MYR301 trial.
In MYR301, 150 participants with chronic hepatitis D were randomized to immediate bulevirtide 2 mg daily, immediate bulevirtide 10 mg daily, or delayed treatment. The week 96 report found that responses were maintained or improved between weeks 48 and 96, with similar combined, virologic, and biochemical response rates between the 2 mg and 10 mg groups. Some patients with weak early virologic response still improved with continued treatment.
The 144-week and post-treatment report adds the claim boundary that many summaries miss. At end of treatment, virologic response rates were high across treatment groups, and combined response occurred in roughly half of participants. During 96 weeks of follow-up after stopping, response rates declined. Some patients maintained undetectable HDV RNA, especially when they had stayed undetectable before stopping, but the pattern does not support a simple finite-course promise for everyone.
The phase 2 interferon-combination literature adds another layer. Bulevirtide with pegylated interferon alfa-2a produced higher rates of HDV RNA undetectability in some arms than pegylated interferon alone. That is clinically interesting, but it is not a casual peptide-stack message. Interferon has specific contraindications, tolerability concerns, psychiatric and autoimmune considerations, and monitoring requirements. Combination evidence belongs in specialist care.
| Evidence setting | Source type | How to read it |
|---|---|---|
| EMA authorization | Hepcludex EPAR and product information | EU authorization covers chronic HDV infection in adults and children from 3 years of age and at least 10 kg with compensated liver disease. |
| MYR301 through week 96 | Open-label randomized phase 3 trial | On-treatment virologic and biochemical responses were maintained or improved through 96 weeks, including in some early suboptimal responders. |
| MYR301 through week 144 and follow-up | Final and post-treatment phase 3 report | On-treatment responses remained meaningful, but virologic and combined response rates declined after treatment discontinuation. |
| Bulevirtide plus pegylated interferon | Phase 2 randomized study | Combination arms generated useful signals, but interferon context and off-treatment durability need careful clinical interpretation. |
A restrained summary is the accurate one. Human evidence indicates that bulevirtide can reduce HDV replication and improve biochemical markers in selected chronic hepatitis D patients during treatment. It does not prove a universal cure, a supplement-style liver protocol, or a research-vial equivalent to Hepcludex.
Safety, Monitoring, And Product Limits
The EMA overview lists raised bile salts in the blood, headache, itching, and injection-site reactions among the most common side effects. It also identifies flare-up of liver inflammation after stopping Hepcludex as the most common serious side effect. That stopping issue fits the MYR301 follow-up signal: discontinuation can change the risk picture.
Bile acid elevation is not a minor label footnote. Bulevirtide blocks a bile-acid transporter, so bile-salt increases are mechanism-linked. The phase 2 study described dose-dependent bile acid elevations that were reversible after completing treatment. A source-aware discussion has to keep that pharmacology in view rather than treating side effects as generic injection irritation.
Injection-site reactions still matter. The injection-site reaction guide explains why local reactions can reflect product, route, technique, excipients, sterility, and immune response. For Hepcludex, the official product context is essential. For research-market products, those assumptions do not carry over.
The reconstitution calculator and the reconstitution math guide can help readers understand concentration and volume language. They cannot evaluate HDV RNA response, compensated versus decompensated liver disease, HBV coinfection treatment, bile-salt monitoring, pregnancy context, or whether a product is lawfully and clinically appropriate.
How To Check Bulevirtide Claims
First, identify the claim. "Hepcludex is authorized in the EU for chronic hepatitis D in a defined compensated-liver-disease population" is different from "bulevirtide cures hepatitis" or "an antiviral peptide supports the liver."
Second, identify the source category. Regulator pages and PubMed-indexed clinical trials can support label and evidence summaries. Forum posts, seller pages, and unlabeled vials cannot establish patient selection, product quality, dosing, monitoring, or legal status.
Third, ask whether the evidence is on-treatment or off-treatment. MYR301 shows meaningful on-treatment responses, but post-treatment follow-up also shows response decline after discontinuation in many patients. A claim that quotes end-of-treatment response without stopping data is incomplete.
Fourth, separate HDV from broader immune language. The thymosin alpha-1 evidence guide and LL-37 guide show how easy it is to overextend immune or antimicrobial concepts. Bulevirtide is not validated by those topics, and those topics are not validated by bulevirtide.
Fifth, check geography and date. EMA authorization, Canadian or Australian availability, and U.S. FDA status are not interchangeable. Product information can also change. A serious page should state which regulator or trial record it is using and when the source was checked.
FAQ
Is bulevirtide a peptide?
Yes. Bulevirtide is a peptide-derived antiviral entry inhibitor developed for chronic hepatitis D treatment in specific regulated contexts.
Is Hepcludex approved in the European Union?
Yes. EMA lists Hepcludex as authorized in the EU, with product information updated in March 2026. Regional status elsewhere should be checked separately.
Does bulevirtide cure hepatitis D?
The evidence supports HDV RNA and ALT response in selected patients during treatment. The 144-week follow-up data show that responses often decline after stopping, so cure language is not appropriate.
Can Hepcludex evidence be applied to research peptides sold online?
No. The evidence concerns a regulator-reviewed prescription product, defined trial protocols, and HDV clinical care. It does not validate unapproved products or seller protocols.
References
- Hepcludex, European Medicines Agency.
- Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta: NCT03852719, ClinicalTrials.gov.
- Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial, Journal of Hepatology / PubMed.
- 144 Weeks of bulevirtide monotherapy for chronic hepatitis D: Final and posttreatment results from a Phase 3 randomized trial, Journal of Hepatology / PubMed.
- Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNalpha-2a as Treatment for Chronic Hepatitis Delta, Liver International / PubMed.
- Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease, Gut / PubMed.
- Bulevirtide: First Approval, Drugs / PubMed.
- Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies, Journal of Hepatology / PubMed.
- Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide, Journal of Hepatology / PubMed.
Disclaimer
This page is educational and is not medical advice. It does not provide hepatitis D diagnosis, antiviral treatment recommendations, medication-starting or stopping guidance, reconstitution guidance, dosing, sourcing, compounding, or individualized safety advice for bulevirtide, Hepcludex, hepatitis D, hepatitis B coinfection, or related products. HDV testing, liver disease staging, antiviral selection, treatment duration, stopping decisions, and monitoring should be handled by qualified clinicians using current regulator materials, trial evidence, and patient-specific risk factors.
Next steps
Continue with the closest guide, peptide profile, or research tool.
